CRA was retained by the claimant in an arbitration regarding the breach of a license agreement relating to pharmaceutical manufacturing technology. In addition to quantifying damages, the CRA team also provided opinions relating to the value of market exclusivity for pharmaceuticals and the relative value of the licensed patented and non-patented intellectual property at issue in the case. Dr. Sean Sheridan submitted two expert reports and provided testimony in deposition and at the arbitration hearing.
Patent damages jury verdicts aren't always end of the story
It has been over three years since Intel Corporation was ordered by a federal jury to pay VLSI Technology LLC over $2 billion in damages. During that time, the...